voxilaprevir
Selected indexed studies
- Voxilaprevir. (, 2006) [PMID:29999978]
- Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C. (Infect Drug Resist, 2019) [PMID:31413603]
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. (Ann Pharmacother, 2018) [PMID:29115151]
_Worker-drafted node — pending editorial review._
Connections
voxilaprevir is a side effect of
Sources
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. (2018) pubmed
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. (2018) pubmed
- Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C. (2019) pubmed
- Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C. (2019) pubmed
- Voxilaprevir. (2006) pubmed
- Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients. (2019) pubmed
- Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. (2022) pubmed
- The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis. (2023) pubmed
- Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection. (2023) pubmed
- Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis. (2023) pubmed